Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert

Type of Relationship with Industry

Catapano Alberico Chapman John

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Cardiovascular (2014) - Esteve : Cardiovascular (2014)

- Merck Sharp & Dohme : Cardiovascular (2014-2015-2016)

- Kowa : Cardiovascular (2014-2015-2016)

- Astra Zeneca : Cardiovascular (2014-2016)

- Pfizer : Cardiovascular (2014-2016)

- Sanofi Aventis : Cardiovascular (2014-2016)

- Aatra Zeneca : Cardiovascular (2015)

- Recordati International : Cardiovascular (2015-2016)

- Amgen Inc : Cardiovascular (2016)

- Aegerion : Cardiovascular (2016)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Cardiovascular (2015) - Pfizer : Cardiovascular (2015)

- Sanofi Aventis : Cardiovascular (2015)

- Aegerion : Cardiovascular (2015)

D - Research funding (departmental or institutional). - Pfizer : Cardiovascular (2015-2016) - Sanofi Aventis : Cardiovascular (2015-2016)

- Merck Sharp & Dohme : Cardiovascular (2015-2016)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lilly : dyslipidemia (2014) - Merck Sharp & Dohme : dyslipidemia (2014)

25/08/2016

Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert

Type of Relationship with Industry

Chapman John

- Kowa : dyslipidemia (2014) - cerenis : HDL (2014) - Amgen : hypercholesterolemia (2014) - Sanofi Aventis : hypercholesterolemia (2014) - Regeneron : hypercholesterolemia (2014) - Astra Zeneca : hypertriglyceridemia (2014) - Unilever : nutraceuticals (2014) - Unilever : human Nutrition and CVD (2015) - Kowa : lipid lowering and CVD (2015) - MSD : lipid lowering and CVD (2015) - Astrazeneca : lipid lowering, dyslipidemia and CVD (2015) - Amgen : PCSK9 inhibition (2015) - Sanofi-Regeneron : PCSK9 inhibition (2015) - Servier : Atherosclerotic vascular disease (2016) - Unilever : Lipid lowering (2016) - Amgen : Lipid lowering therapies (2016) - Sanofi-Regeneron : Lipid lowering therapies (2016) D - Research funding (departmental or institutional). - Kowa : dyslipidemia (2014) - Pfizer : diabetic dyslipidemia (2014-2015) - Kowa : Lipid lowering, dyslipidemia and CVD (2015) - Pfizer : Statins (2016) - Kowa : Statins (2016)

25/08/2016

Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert

Type of Relationship with Industry

Cooney Marie Therese De Backer Guy Drexel Heinz Graham Ian Maklim

Hoes Arno

Nothing to be declared (2014-2015-2016)

Nothing to be declared (2014-2016)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Lipid lowering drugs (2015)

- Sanofi Aventis : Lipid lowering drugs (2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck and others : diabetes, hypertension, lipids (2014-2015-2016)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Advisory Board (2014-2015)

- Merck Sharp & Dohme : CVD risk factor audit (2014-2015)

- MSD : Prevention and risk assessment (2016)

D - Research funding (departmental or institutional). - Merck Sharp & Dohme : CVD risk factor audit (2014)

E - Research funding (personal). - World Health Organisation : Co-Chair of Expert Advisory Group developing a new CVD risk estimation system (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We

perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)

- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2014)

D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We

perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)

25/08/2016

Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert

Type of Relationship with Industry

Hoes Arno Jennings Catriona Sian Landmesser Ulf

Pedersen Terje

- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2015-2016) Nothing to be declared (2014-2015-2016)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Advisory Board, Speakers fee (2014) - Sanofi Aventis : Advisory Board, Speakers fee (2014)

- MSD : Advisory Board, Speakers fee (2014)

- Roche Pharma : Research grant, Advisory Board (2014)

- Pfizer : Research grant, Speakers fee (2014)

- St. Jude : Advisory Board fees (2015-2016)

- Amgen : Speaker fees (2015-2016)

- Pfizer : Speaker fees (2015-2016)

- Sanofi Aventis : Speaker fees (2015-2016)

- Berlin Chemie AG : Speaker fees (2015-2016)

- Roche Pharma : Speaker fees (2015-2016)

- MSD : Speaker fees, Advisory Board fees (2015-2016)

- Boehringer-Ingelheim : Speaker fees (2016)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : Lipid lowering drugs (2014) - Amgen : PCSK9 inhibitor (under deveelopment) (2014)

- Amgen : Cholesterol lowering (2015-2016)

25/08/2016

Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert

Type of Relationship with Industry

Pedersen Terje Reiner Zeljko Riccardi Gabriele

- Merck Sharp & Dohme : Cholesterol lowering (2015-2016)

- Sanofi Aventis : Cholesterol lowering (2016)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : Lipid lowering drugs (2014) - Amgen : PCSK9 inhibitor (under development) (2014)

- Merck Sharp & Dohme : Cholesterol lowering (2015)

- Amgen : Cholesterol lowering (2015-2016)

D - Research funding (departmental or institutional). - Amgen : Cholesterol lowering (2016) - Merck Sharp & Dohme : Cholesterol lowering (2016)

Nothing to be declared (2016)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Synageva : LAL-D (2014) - Sanofi Aventis : PCSK9 inihibitor (2014)

- Sanofi Aventis : PCSK9 inhibitor (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Mylan : antilipemics (2015)

D - Research funding (departmental or institutional). - Sanofi Aventis : mipomersen (2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : diabetes (2014-2015-2016) - Takeda Pharmaceuticals : diabetes (2014-2015-2016)

- Aventis : diabetes (2014-2015-2016)

- Barilla Center for food and nutrition Foundation : nutrition (2014-2015-2016)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Barilla Food Company : nutrition (2014-2015-2016)

25/08/2016

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download